Eli Lilly's Omvoh Achieves Long-Term Steroid-Free Remission in Crohn's Disease

Eli Lilly and Company has announced groundbreaking long-term data for its inflammatory bowel disease (IBD) drug, Omvoh (mirikizumab), signaling a major advancement in chronic disease management.

According to the Phase 3 VIVID-2 trial results presented recently, more than 90% of Crohn’s disease patients who reached steroid-free remission after one year successfully maintained that control through three years of continuous monthly treatment. Specifically, 91.2% of the one-year responder cohort maintained corticosteroid-free clinical remission, demonstrating the drug's sustained anti-inflammatory effect.

The treatment, which stands as the only IL-23p19 inhibitor to show such durable efficacy over three years in Crohn's and four years in ulcerative colitis, goes beyond basic clinical remission to offer significant symptom relief. Over 82% of patients reported sustained, meaningful reductions in bowel urgency, a highly disruptive symptom of the disease. Furthermore, Omvoh demonstrated a remarkable ability to fundamentally alter the disease trajectory, with trial data revealing exceptionally low rates of severe complications, including surgeries and hospitalizations, across both Crohn's disease and ulcerative colitis.

The medical community's positive reception of these long-term results has also resonated strongly on Wall Street. Following the announcement, Eli Lilly's stock (LLY) saw an upward movement, supported by financial analysts who currently maintain a consensus "Strong Buy" rating for the pharmaceutical giant.

Omvoh gained FDA approval for ulcerative colitis in 2023 and for Crohn's disease in early 2025, and is now approved in 47 countries. Analysts forecast that the drug will cross into blockbuster sales territory by 2031. As Eli Lilly expands its footprint in the lucrative IBD market—projected to reach $13.8 billion by 2032—Omvoh positions the company as a formidable competitor against established treatments like AbbVie's Skyrizi and Johnson & Johnson's Stelara. With its robust drug pipeline and proven long-term efficacy, Omvoh represents both a beacon of hope for patients and a solid growth driver for investors.

---

🔖 Sources

Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)

Eli Lilly’s Omvoh achieves 91% Crohn’s steroid-free remission at three years

Eli Lilly Stock (LLY) Rises as Company Reports Progress with Crohn’s Disease Treatment

---

Keywords: Steroid-Free Remission in Crohn's Disease

Steroid-Free Remission in Crohn's Disease

---